Cassava Sciences | PTIE - Assets


Cassava Sciences reported $108.37M in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
Abbott USD 110.43B 23.72B Mar/2026
Amgen USD 92.5B 1.92B Mar/2026
Biogen USD 29.48B 43.6M Mar/2026
Cara Therapeutics USD 32.07M 6.95M Dec/2025
Cassava Sciences USD 108.37M 9.99M Mar/2026
Eisai JPY 1.45T 37.11B Mar/2026
Eli Lilly USD 116.58B 4.1B Mar/2026
Geron USD 534.12M 36.42M Mar/2026
J&J USD 200.89B 1.68B Mar/2026
Merck USD 128.68B 8.18B Mar/2026
Novartis USD 118.53B 7.58B Mar/2026
Novavax USD 1.04B 133.35M Mar/2026
Pfizer USD 207.62B 542M Mar/2026
Roche Holding CHF 100.7B 5.94B Dec/2025